Dxcover, a UK-based company improving early cancer detection with its AI-powered multiomic technology, has announced the launch of its United States headquarters in Nashville, Tennessee. The move reflects Dxcover’s commitment to commercialising its PANAROMIC cancer test in the world’s biggest life sciences market.
Dxcover’s innovative Drop. Dry. Detect. approach offers a cost-effective, high-throughput, non-invasive cancer screening platform. The new facilities will allow the company to forge partnerships with local biotech and healthcare organisations, advance local manufacturing of its innovative infrared spectroscopy platform and serve as a research and development hub aimed at extending Dxcover’s leadership in cancer diagnostics innovation.
Matthew J. Baker, Ph.D., CEO and Co-founder of Dxcover said: “The launch of our U.S. headquarters in Nashville represents a major value-building milestone for Dxcover as we accelerate our mission to make early cancer detection accessible everywhere.
“Nashville is well known for its dynamic business environment in the healthcare field and we look forward to collaborating with research institutes, health organisations, and biotech start-ups to promote precision medicine and enhance early cancer detection solution access. Organisations such as Life Science Tennessee and BioTN are vital to the enhancement of life sciences innovation, and Dxcover is eager to be an active member of this growing collective.”
Dxcover’s PANAROMIC technology is transforming cancer screening through a multiomic approach through infrared spectroscopy and AI-driven spectral analysis. Unlike genetic-marker-based tests, Dxcover’s platform captures the complete biological signature from a tiny blood sample, enabling earlier diagnosis and better patient outcomes.
The technology is scalable and already demonstrated proof-of-concept in various forms of cancer, including brain, colorectal, lung, and pancreatic cancers. Dxcover aims to bring high-tech diagnostics to underserved populations, enhancing global healthcare equity.
Baker spoke to Med-Tech Insights in December 2024, and talked about the use of AI in the PANAROMIC technology: “The AI enables us to find the differences between cancerous and non-cancerous populations. We are able to train an algorithm to identify this difference and then we freeze that algorithm. Currently, we are using our brain cancer detection algorithm in the largest, to our knowledge, brain cancer diagnostic study that has ever been done. This is recruiting 2,200 patients across seven European sites.”
